The selective and potent PARP-1 inhibitor AZD5305 also has PARP-1-DNA trapper activity, shown in a preclinical in vivo patient-derived xenograft (PDX) model of BRCA mutant breast cancer (HBCx-17) (Johannes et al., 2021). The gene discussed is PARP1; the disease is breast carcinoma.